Skip to main content

Avalo Therapeutics, Inc.

AVTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001534120

In the last 90 days, Avalo Therapeutics, Inc. insiders filed 0 open-market purchases and 9 sales; 125 institutions reported holding it in 13F filings for Q2 2026, worth $1.34B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Avalo Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
9 filings
3 insiders, $2.04M in total
Insiders trading
3
Net value
−$2.04M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Avalo Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Avalo Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Sullivan Christopher RyanChief Financial Officer39,900Sep 18, 202612
Doyle MittieChief Medical Officer51,776Sep 1, 202616
Riley JenniferChief Strategy Officer37,041Aug 12, 20265
Philip Ron MDirector–Jul 2, 20262
Lind Kevin RobertDirector–Jul 2, 20265
Jain RitaDirector–Jul 2, 20265
Varki PaulChief Legal Officer32,576Jun 12, 20265
Kaplan GillaDirector6,333Jun 4, 20262
Heffernan Michael ThomasDirector–Jun 4, 20261
Kantoff AaronDirector6,333Jun 4, 20262
Truex SamanthaDirector6,333Jun 4, 20262
Neil Garry ArthurChief Executive Officer190,314May 26, 20263
Chan MitchellDirector3,166May 7, 20262
Goldman JonathanDirector3,166Mar 31, 20262
Boyd TaylorChief Business Officer–Mar 2, 20262
Almenoff June SherieDirector3,167Jun 18, 20250
Persson MagnusDirector–Dec 21, 20230
Armistice Capital, LLC10% Owner731,458IndirectJun 28, 20230
Armistice Capital Master Fund Ltd.10% Owner731,458IndirectJun 28, 20230
Boyd Steven10% Owner731,458IndirectJun 28, 20230
Caissa Capital Management ltd.10% Owner0Jun 27, 20230
Miller Joseph MDirector–Apr 4, 20220
Smolinski StephenChief Commercial Officer–Jan 6, 20220
Harrell James Archie JrChief Commercial Officer36,766Dec 14, 20210
Wilkins H JeffreyChief Medical Officer33,373Dec 14, 20210
Greenway Schond L.CFO3,883Dec 14, 20210
Gutry PhilDirector–Dec 3, 20210
Bruhn Suzanne LouiseDirector–Nov 12, 20210
Cola Michael FChief Executive Officer–Oct 4, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 18, 2026 (view filing)4:10 PM ETSep 162 daysSullivan Christopher RyanChief Financial OfficerSSale−12.4K$16.33−$202.4K−23.7%39.9K after10b5-1
Sep 11, 2026 (view filing)4:10 PM ETSep 101 daySullivan Christopher RyanChief Financial OfficerSSale−10.2K$17.62−$179.5K−20.3%39.9K after10b5-1
Sep 1, 2026 (view filing)4:38 PM ETAug 284 daysDoyle MittieChief Medical OfficerSSale−679$20.00−$13.6K−1.3%51.8K after10b5-1
Aug 19, 2026 (view filing)4:10 PM ETAug 17-182 daysSullivan Christopher RyanChief Financial OfficerSSale−72.7K$19.94−$1.45M−64.6%39.9K after3 lots10b5-1
Aug 19, 2026 (view filing)4:10 PM ETAug 172 daysDoyle MittieChief Medical OfficerSSale−1.00K$20.00−$20.0K−1.9%51.8K after10b5-1
Aug 12, 2026 (view filing)4:10 PM ETAug 111 dayRiley JenniferChief Strategy OfficerSSale−2.65K$19.59−$52.0K−6.7%37.0K after
Aug 12, 2026 (view filing)4:10 PM ETAug 102 daysDoyle MittieChief Medical OfficerSSale−679$20.00−$13.6K−1.3%51.8K after10b5-1
Jul 29, 2026 (view filing)4:05 PM ETJul 272 daysDoyle MittieChief Medical OfficerSSale−1.00K$20.00−$20.0K−1.9%51.8K after10b5-1
Jul 2, 2026 (view filing)4:05 PM ETJun 302 daysDoyle MittieChief Medical OfficerSSale−4.65K$20.00−$93.1K−8.2%51.8K after10b5-1
Jun 25, 2026 (view filing)Jun 232 daysDoyle MittieChief Medical OfficerSSale−1.45K$18.00−$26.1K−2.7%51.8K after10b5-1
Jun 1, 2026 (view filing)May 284 daysDoyle MittieChief Medical OfficerSSale−679$16.00−$10.9K−1.4%47.1K after10b5-1
May 19, 2026 (view filing)May 154 daysDoyle MittieChief Medical OfficerSSale−3.00K$18.76−$56.3K−45.3%3.62K after10b5-1
May 11, 2026 (view filing)May 74 daysSullivan Christopher RyanChief Financial OfficerSSale−18.6K$24.12−$448.8K−97.8%423 after10b5-1
May 7, 2026 (view filing)May 5-62 daysDoyle MittieChief Medical OfficerSSale−108.2K$20.61−$2.23M−96.8%3.62K after6 lots10b5-1
May 7, 2026 (view filing)May 61 daySullivan Christopher RyanChief Financial OfficerSSale−47.0K$20.18−$948.6K−99.1%423 after5 lots10b5-1
May 7, 2026 (view filing)May 61 dayChan MitchellDirectorSSale−3.17K$22.88−$72.5K−50.0%3.17K after10b5-1
May 7, 2026 (view filing)May 61 dayVarki PaulChief Legal OfficerSSale−75.1K$20.17−$1.51M−95.4%3.63K after5 lots10b5-1
May 1, 2026 (view filing)Apr 29-302 daysSullivan Christopher RyanChief Financial OfficerSSale−16.9K$13.16−$222.6K−97.6%423 after2 lots10b5-1
Apr 8, 2026 (view filing)Apr 62 daysDoyle MittieChief Medical OfficerSSale−3.97K$18.01−$71.5K−52.3%3.62K after10b5-1
Apr 3, 2026 (view filing)Apr 12 daysDoyle MittieChief Medical OfficerSSale−679$16.00−$10.9K−15.8%3.62K after10b5-1
Apr 3, 2026 (view filing)Apr 1-22 daysSullivan Christopher RyanChief Financial OfficerSSale−16.0K$16.96−$270.6K−47.9%17.3K after4 lots10b5-1
Mar 18, 2026 (view filing)Mar 162 daysDoyle MittieChief Medical OfficerSSale−25.5K$16.15−$411.7K−87.6%3.62K after10b5-1
Nov 17, 2025 (view filing)Nov 143 daysGoldman JonathanDirectorSSale−11.4K$14.34−$163.0K−100.0%0 after2 lots
Nov 14, 2024 (view filing)Nov 12-132 daysAlmenoff June SherieDirectorPPurchase+1.00K$12.75+$12.8KNew position1.00K after2 lots
Jun 28, 2023 (view filing)6:12 PM ETJun 26-272 daysArmistice Capital, LLC and 2 others10% OwnerSSale−3.68M$0.5888−$2.17M−83.4%731.5K after2 lots
Jun 27, 2023 (view filing)Jun 261 dayCaissa Capital Management ltd.10% OwnerPPurchase−1.43M$0.64−$912.4K−100.0%0 after
Jun 27, 2023 (view filing)Jun 261 dayCaissa Capital Management ltd.10% OwnerPPurchase−182.3K$0.62−$113.0K−100.0%0 after
Jun 20, 2023 (view filing)Jun 15-205 daysCaissa Capital Management ltd.10% OwnerPPurchase+8.16K$3.87+$31.6K+0.6%1.43M after3 lots
Jun 14, 2023 (view filing)Jun 12-142 daysCaissa Capital Management ltd.10% OwnerPPurchase+16.9K$3.77+$63.6K+1.2%1.42M after3 lots
Jun 13, 2023 (view filing)Jun 94 daysSullivan Christopher RyanChief Financial OfficerPPurchase+511$3.42+$1.75K+68.0%1.26K after
Jun 13, 2023 (view filing)Jun 94 daysNeil Garry ArthurCEO and Chairman of the BoardPPurchase+4.00K$3.42+$13.7K+43.4%13.2K after
Jun 9, 2023 (view filing)Jun 7-92 daysCaissa Capital Management ltd.10% OwnerPPurchase+14.4K$3.91+$56.4K+1.0%1.40M after3 lots
Jun 2, 2023 (view filing)May 312 daysCaissa Capital Management ltd.10% OwnerPPurchase+844$2.87+$2.42K+0.1%1.39M after
May 30, 2023 (view filing)May 25-305 daysCaissa Capital Management ltd.10% OwnerPPurchase+2.67K$2.80+$7.47K+0.2%1.39M after2 lots
May 24, 2023 (view filing)May 24Same dayCaissa Capital Management ltd.10% OwnerPPurchase+9.00K$2.98+$26.8K+0.7%1.38M after2 lots
May 22, 2023 (view filing)May 18-224 daysCaissa Capital Management ltd.10% OwnerPPurchase+26.6K$3.36+$89.4K+2.0%1.37M after3 lots
May 16, 2023 (view filing)May 12-164 daysCaissa Capital Management ltd.10% OwnerPPurchase+4.38K$2.52+$11.0K+0.3%1.35M after3 lots
May 8, 2023 (view filing)May 4-84 daysCaissa Capital Management ltd.10% OwnerPPurchase+25.0K$2.77+$69.3K+1.9%1.34M after3 lots
Apr 27, 2023 (view filing)Apr 25-272 daysCaissa Capital Management ltd.10% OwnerPPurchase+7.50K$2.99+$22.4K+0.6%1.32M after3 lots
Apr 24, 2023 (view filing)Apr 20-244 daysCaissa Capital Management ltd.10% OwnerPPurchase+17.5K$3.07+$53.6K+1.4%1.31M after2 lots
Apr 18, 2023 (view filing)Apr 17-181 dayCaissa Capital Management ltd.10% OwnerPPurchase+25.0K$2.95+$73.8K+2.0%1.29M after2 lots
Apr 11, 2023 (view filing)Apr 10-111 dayCaissa Capital Management ltd.10% OwnerPPurchase+56.3K$2.53+$142.4K+4.7%1.27M after2 lots
Feb 9, 2023 (view filing)4:32 PM ETFeb 72 daysArmistice Capital, LLC and 2 others10% OwnerPPurchase+450.0K––+11.3%4.42M after
Feb 9, 2023 (view filing)4:32 PM ETFeb 72 daysArmistice Capital, LLC and 2 others10% OwnerPPurchase+450.0K–––450.0K afterDerivative
Dec 12, 2022 (view filing)Dec 93 daysNeil Garry ArthurCEO and Chairman of the BoardPPurchase+2.08K$4.42+$9.21K+29.2%9.22K after
Mar 14, 2022 (view filing)5:38 PM ETMar 10-144 daysArmistice Capital, LLC and 2 othersDirector, 10% OwnerPPurchase+226.0K$0.6723+$151.9K+0.5%47.6M after3 lots
Mar 7, 2022 (view filing)6:09 PM ETMar 3-74 daysArmistice Capital, LLC and 2 othersDirector, 10% OwnerPPurchase+510.0K$0.6748+$344.1K+1.1%47.4M after3 lots
Feb 28, 2022 (view filing)5:53 PM ETFeb 24-254 daysArmistice Capital, LLC and 2 othersDirector, 10% OwnerPPurchase+140.0K$0.7986+$111.8K+0.3%46.8M after2 lots
Feb 22, 2022 (view filing)6:37 PM ETFeb 17-225 daysArmistice Capital, LLC and 2 othersDirector, 10% OwnerPPurchase+288.0K$0.804+$231.6K+0.6%46.7M after3 lots
Jan 20, 2022 (view filing)6:14 PM ETJan 18-202 daysArmistice Capital, LLC and 2 othersDirector, 10% OwnerPPurchase+312.0K$0.8798+$274.5K+0.7%46.4M after3 lots